This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.

Inclusion Criteria:

• Voluntarily participate in the study and sign the informed consent.
• Age≥18 years.
• Subjects with relapsed or refractory lymphoma.
• Subjects with at least one measurable tumor lesion.
• ECOG 0-2.
• Life expectancy≥3 months.
• Adequate organ functions.

Exclusion Criteria:

• Subjects who had received anticancer therapy or radiotherapy within 21 days or 5 half-lives (whichever is shorter) before enrollment or received adoptive cellular immunotherapy within 12 weeks.
• Subjects who had received allogeneic hematopoietic stem cell transplantation or organ transplantation or received autologous hematopoietic stem cell transplantation within 3 months.
• Subjects with primary or secondary CNS lymphoma.
• History of another malignancy within 3 years before the first dose of investigational drug.
• History of active autoimmune diseases.
• Systemic immunosuppressive therapy within 2 weeks prior to the first dose of investigational drug.
• Subjects who experienced grade 3 or above immune-related adverse events (irAE) .
• Documented history of uncontrolled systemic diseases.
• Subjects who were allergic to any composition of investigational drug.
• Major surgery within 28 days prior to first dose of investigational drug.
• Subjects with active infection.
• Preexisting treatment related toxicity Grade ≥ 2 (except alopecia).
• Subjects with poor treatment compliance.
• Use of any investigational drug or device within 28 days prior to the first dose of investigational drug.
• Live vaccine was administered within 28 days prior to first dose of investigational drug.
• Pregnant or lactating women.